CASE COMMENTS : ANTICOMPETITIVES PRACTICES - ARTICLE 81 EC - AGREEMENTS - DECISIONS AND CONCERTED PRACTICES - RESTRICTION OF PARALLEL TRADE IN MEDICINES - RESTRICTION OF COMPETITION BY OBJECT - CONTRIBUTION TO PROMOTING TECHNICAL PROGRESS - BURDEN OF PROOF

Exemption: The ECJ upholds the analysis of the CFI on restrictions of parallel trades in medicines and restriction of competition by oject (GlaxoSmithKline)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. ECJ, 6 October 2009, GlaxoSmithKline and Others, cases C-501/06, C-513/06, C-515/06 and C-519/06P. By Decision 2001/791/EC of 8 May 2001 relating to a proceeding under Article 81 EC [Cases: IV/36.957/F3, Glaxo Wellcome (notification); IV/36.997/F3, Aseprofar and Fedifar (complaint); IV/37.121/F3, Spain Pharma (complaint); IV/37.138/F3, BAI (complaint); IV/37.380/F3, EAEPC (complaint)] (OJ L 302, p. 1 ; hereinafter 'the contested decision'), the Commission found that Glaxo Wellcome SA (hereinafter 'GW'), a subsidiary of GlaxoSmithKline Services Unlimited (hereinafter 'GSK'), had infringed Article 81(1), EC by concluding an agreement with Spanish

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • European Court of Justice (Luxembourg)

Quotation

Cyril Sarrazin, Exemption: The ECJ upholds the analysis of the CFI on restrictions of parallel trades in medicines and restriction of competition by oject (GlaxoSmithKline), 6 October 2009, Concurrences N° 1-2010, Art. N° 30307, pp. 89-90

Visites 2775

All reviews